Why Regeneron (REGN) Might be Well Poised for a Surge
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research11/4/2026Positive
REGN
Regeneron Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$93.55B
P/E Ratio
19.99
EPS
$45.24
Beta
0.10
52W High
$991.73
52W Low
$590.83
50-Day MA
$804.38
200-Day MA
$742.33
Dividend Yield
0.41%
Profit Margin
28.50%
Forward P/E
13.26
PEG Ratio
1.10
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Fundamentals
| Revenue (TTM) | $16.90B |
| Gross Profit (TTM) | $7.90B |
| EBITDA | $5.65B |
| Operating Margin | 40.50% |
| Return on Equity | 14.90% |
| Return on Assets | 7.59% |
| Revenue/Share (TTM) | $164.24 |
| Book Value | $333.93 |
| Price-to-Book | 2.79 |
| Price-to-Sales (TTM) | 5.54 |
| EV/Revenue | 5.14 |
| EV/EBITDA | 13.90 |
| Quarterly Earnings Growth (YoY) | 35.50% |
| Quarterly Revenue Growth (YoY) | 36.30% |
| Shares Outstanding | $101.63M |
| Float | $96.35M |
| % Insiders | 2.07% |
| % Institutions | 93.06% |
Historical Volatility
HV 10-Day
72.58%
HV 20-Day
54.43%
HV 30-Day
48.75%
HV 60-Day
39.13%
HV Rank
99.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($977.93 target)
4
Strong Buy15
Buy8
Hold1
Strong SellLatest News
REGN vs. ILMN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research11/4/2026Positive
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.
GlobeNewsWire11/2/2026Neutral
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Benzinga11/2/2026Positive
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
Zacks Investment Research10/30/2026Positive
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Seeking Alpha10/30/2026Neutral
Regeneron Is Just Getting Started
Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed resilience despite biosimilar competition; pipeline updates further reinforced Regeneron's momentum. I now expect 2026 revenues to reach $19 billion, a 33% increase, and non-GAAP EPS growth in the low- to mid-50% range.
Seeking Alpha10/30/2026Positive
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.
MarketBeat10/30/2026Positive
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
24/7 Wall Street10/30/2026Positive
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.
24/7 Wall Street10/30/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026